Abemaciclib metabolite M18 hydrochloride (C09-1103-225)

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader Appearance:SolidIC50& Target:CDK4 CDK6In Vitro:Abemaciclib metabolite M18 hydrochloride exhibits T 1/2 of 43.1 hr in plasma in healthy subjects. CDK4/6 inhibitors’ chief mechanism of action is inhibition of retinoblastoma (RB) protein phosphorylation and thus the induction of cell cycle arrest, CIn Vivo:CDK4/6 inhibitors results T-cell persistence and immunologic memory increasing in mice receiving tumor-specific CD8 + T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Biological Activity:Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. Specification: 0.98 Molecular Formula: C25H29ClF2N8O Molecular Weight: 531